Nick Evans

May 3, 2024 | theaustralian.com.au | Ben Packham |Adam Creighton |Nick Evans |James Dowling

The mayor of the Sydney council of Blacktown Tony Bleasdale has died while on a delegation flight returning from China. Mr Bleasdale, 77, spent almost 30 years as a Blacktown councillor, taking on mayoral duties in 2019. No cause of death has been established, but Mr Bleasdale had struggled after a past Covid diagnosis, acting mayor Chris Quilkey said. Mr Bleasdale had recovered well in the past 12 months.

Apr 19, 2024 | theaustralian.com.au | Nick Evans

Pilbara Minerals boss Dale Henderson says the company has seen a strong uplift in lithium pricing in recent months as some producers left the market, but says it is too early to call a sustained recovery in commodity pricing. Pilbara received an average price of $US804 a tonne for its lithium concentrate in the March quarter, but Mr Henderson said pricing had strengthened across the period and continued to do so.

Apr 15, 2024 | theaustralian.com.au | Eddy Sunarto |Jack Quail |Nick Evans

Island Pharma (ASX:ILA) has just reported that a single dose of its ISLA-101 drug achieves blood concentrations shown to be effective against dengue fever. A 24-subject single ascending dose clinical study demonstrated highly positive pharmacokinetic (PK) data and reconfirmed strong safety/tolerability data for the drug.

Apr 15, 2024 | theaustralian.com.au | Jessica Cummins |Jack Quail |Nick Evans

Zinc smelter prices have continued their downward slump this year, opening the doors of opportunity for explorers who were previously operating on fine margins. During times of raw material surplus, smelter prices (the fee for converting concentrates into refined metal) tend to rise, but when they go down, it’s usually a telltale sign the market is in shortfall, and economic deposits can become very lucrative.

Apr 15, 2024 | theaustralian.com.au | Eddy Sunarto |Jack Quail |Nick Evans

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Pointsbet’s (ASX:PBH) decision to abandon its US operations sets it up to capture more market share in Australia, says Jarden Research. Meanwhile, Wilsons Advisory sees big things ahead for Clarity Pharma.